Search
moon
sun

T228. Hypothyroidism and myxedema crisis

A. Introduction and epidemiology

1.
Hypothyroidism : Thyroid hormone์˜ ์ƒ์‚ฐ์ด ๋ถˆ์ถฉ๋ถ„ํ•œ ์ƒํƒœ โ†’ Metabolism์˜ ์ €ํ•˜
2.
๊ณ ๋ น/๋ฐฑ์ธ/์—ฌ์„ฑ(10๋ฐฐ)์—์„œ ๋งŽ์Œ
3.
๋ชจ๋“  ์—ฐ๋ น๊ตฐ์—์„œ Subclinical์ด ๋” ๋งŽ๊ณ  ๊ณ ๋ น ์—ฌ์„ฑ 4~15%์—์„œ ๋ฐœ๊ฒฌ๋จ
4.
ํ˜„์žฌ ์น˜๋ฃŒ๋กœ myxedema coma์˜ ์‚ฌ๋ง๋ฅ ์€ 30~60%

B. Pathophysiology

โ€ข
Thyroxine (T4), triiodothyronine (T3)๊ฐ€ thyroid hormone. ํ˜ˆ์ค‘ ๋น„์œจ์€ 10:1
โ€ข
๋ง์ดˆ์—์„œ T4๊ฐ€ active T3๋กœ ๋ณ€ํ™˜๋˜๊ณ  T4๋ณด๋‹ค 3~4๋ฐฐ ๋” potent
โ€ข
Half life : T4๋Š” 7์ผ, T3๋Š” 1์ผ

B1. ์ผ์ฐจ์„ฑ : Thyroid gland ์ž์ฒด์˜ ๋ฌธ์ œ.

(1) Hashimotoโ€™s thyroiditis๊ฐ€ m/c
(2) ์ˆ˜์ˆ ์  ์ ˆ์ œ์ˆ , radioactive ablation, ๋ช‡ ๊ฐ€์ง€ ์•ฝ๋ฌผ๋„ ์›์ธ
โ€ข
Drugs: Lithium, ฮฑ-interferon, interleukin, tyrosine kinase inhibitors.
โ—ฆ
Amiodarone์€ 14%๊นŒ์ง€ hypothyroidism ์œ ๋ฐœ

B2. ์ด์ฐจ์„ฑ : ์‹œ์ƒํ•˜๋ถ€-๋‡Œํ•˜์ˆ˜์ฒด ์ถ•์˜ ์ด์ƒ

(1) TSH (pituitary gland), thyrotropin-releasing hormone (hypothalamus) ๊ฒฐํ•
(2) Hypothalamic-pituitary axis์˜ ์ด์ƒ์œผ๋กœ ์ธํ•œ ์ค‘์ถ”์„ฑ ์›์ธ

B3. Euthyroid sick syndrome

(1) Low T3 or T4์™€ normal or low TSH๋ฉฐ ์ž„์ƒ์ ์œผ๋กœ euthyroid ํ™˜์ž
(2) ์ฃผ๋กœ critically ill or severe systemic illness๊ฐ€ ์žˆ๋Š” ํ™˜์ž

C. Clinical features of hypothyroidism

Additional cardiopulmonary findings : Angina, Bradycardia, Distant heart sounds from pericardial effusion, Low voltage on ECG, Pleural effusion, CMP, Hypoventilation

D. Clinical features of myxedema crisis

โ€ข
Myxedema crisis (metabolic and multiorgan decompensation) : Uncorrected hypothyrodism, Mental status changes or coma, and hypothermia (<35.5โ…ฃ)
โ€ข
Figure 228-1์˜ ์ฆ์ƒ์€ ๋ฌผ๋ก  ์„œ๋งฅ, ์ €ํ˜ˆ์••, ์ €์ฒด์˜จ, ํ˜ธํก์ €ํ•˜ ๋ฐ ์˜์‹ ์ €ํ•˜/ํ˜ผ์ˆ˜๋„ ๋™๋ฐ˜

D1. ๊ฐ‘์ƒ์„  ๊ธฐ๋Šฅ ์ €ํ•˜ ์ƒํƒœ์—์„œ myxedema ์œ ๋ฐœ ์š”์ธ

โ€“ ๊ฐ์—ผ, ๋งˆ์ทจ์ œ, ์ถ”์œ„ ๋…ธ์ถœ, ์™ธ์ƒ, ์‹ฌ๊ทผ๊ฒฝ์ƒ‰, ์‹ฌ๋ถ€์ „, ๋‡Œ๊ฒฝ์ƒ‰, ์œ„์žฅ๊ด€ ์ถœํ˜ˆ, ์ˆ˜์ˆ , ํ™”์ƒ, ์•ฝ๋ฌผ, ํ˜ธ๋ฅด๋ชฌ ๋ณด์ถฉ ๋ถ€์žฌ

D2. ์ €์ฒด์˜จ

โ€ข
์ •์ƒ ์ฒด์˜จ์ผ ์‹œ underlying infection ๊ฐ๋ณ„ ํ•„์š”
โ€ข
์ €์ฒด์˜จ์€ ๊ต‰์žฅํžˆ ํ”ํ•˜์—ฌ ์ •์ƒ ์ฒด์˜จ์ด ์˜คํžˆ๋ ค ๊ฐ์—ผ ์ƒํƒœ์ผ ์ˆ˜ ์žˆ์Œ.
โ€ข
ํ™˜์ž์˜ ๋ฐ˜์€ SBP <100mmHg. ์—ด, ๋นˆ๋งฅ, ๋ฐœํ•œ์ด ์—†์ง€๋งŒ ๊ฐ์—ผ ์ƒํƒœ์ผ ์ˆ˜ ์žˆ์Œ.

D3. ์˜์‹์ €ํ•˜

โ€ข
ํ˜ธํก ์ €ํ•˜๋กœ ์ธํ•œ CO2 narcosis๋‚˜ ์ €ํ˜ˆ๋‹น์œผ๋กœ ์ธํ•œ ์˜์‹ ์ €ํ•˜ ๊ฐ€๋Šฅ์„ฑ
โ€ข
ํ‰์ˆ˜๋„ ํ”ํ•˜๊ณ  upper airway edema๋กœ ์ธํ•œ obstruction ๊ฐ€๋Šฅ์„ฑ
โ€ข
๋งˆ์ทจ์ œ ๋“ฑ์˜ ๋Œ€์‚ฌ๊ฐ€ ๋–จ์–ด์ ธ ์ด๋กœ ์ธํ•œ ์˜์‹ ์ €ํ•˜ ๊ฐ€๋Šฅ์„ฑ
โ€ข
์ƒ๊ธฐ condition์—์„œ ์ €์ฒด์˜จ์€ ๊ต‰์žฅํžˆ ํ”ํ•˜์—ฌ ์ •์ƒ ์ฒด์˜จ์ด ์˜คํžˆ๋ ค ๊ฐ์—ผ ์ƒํƒœ์ผ ์ˆ˜ ์žˆ์Œ.

E. Diagnosis

โ€ข
Hypothyroidism : Lab ๊ฒฐ๊ณผ๋กœ ์ง„๋‹จ
โ€ข
Myxedema crisis : ์ž„์ƒ์ ์œผ๋กœ ์ง„๋‹จ.

E1. Laboratory evaluation (TSH, T4, T3, cortisol ์น˜๋ฃŒ ์ „ ์‹œํ–‰)

(1) ๊ฐ‘์ƒ์„  ๊ธฐ๋Šฅ๊ฒ€์‚ฌ

โ€ข
High TSH + low total or fT4 & T3 โ†’ Primary hypothyroidism
โ€ข
Low TSH + low total or fT4 & T3 โ†’ Secondary hypothyroidism
โ€ข
fT4 & T3 assay๊ฐ€ ๋ฐ”๋žŒ์ง โ†’ Protein binding์˜ ์˜ํ–ฅ์„ ๋ฐ›์ง€ ์•Š๊ธฐ ๋•Œ๋ฌธ
โ€ข
์•ฝ๋ฌผ์ƒํ˜ธ์ž‘์šฉ์œผ๋กœ TFT ๋ณ€ํ•ด ์žˆ์„ ์ˆ˜ ์žˆ์œผ๋‚˜ ์•ฝ๋ฌผ ์ค‘๋‹จ ํ›„ ๋ณดํ†ต ํ˜ธ์ „๋จ (์•ฝ๋ฌผ : Tab 228-1) โ†’ ์น˜๋ฃŒ ์ „ ํ›„๋กœ TFT ์‹œํ–‰ํ•˜์—ฌ์•ผ ํ•จ

(2) Anemia

โ€ข
๊ฐ‘์ƒ์„  ๊ธฐ๋Šฅ ์ €ํ•˜๋กœ ์ธํ•œ menorrhagia์˜ ๊ฒฝ์šฐ IDA type (microcytic) anemia

(3) Hyponatremia

โ€ข
ADH ์˜ ์ฆ๊ฐ€ + Impaired free water clearance โ†’ Hyponatremia ์œ ๋ฐœ

(4) Hypoglycemia

โ€ข
Gluconeogenesis ๊ฐ์†Œ / insulin clearance ๊ฐ์†Œ / adrenal insufficiency ํ˜น์€ GH ๊ฐ์†Œ โ†’ Hypoglycemia ์œ ๋ฐœ

(5) ABGA : Hypoxemia, Hypercapnia, MA & RA

(6) ECG : MI / bradytarrhythmias / heart block ํ™•์ธ

(7) CXR : Pneumonia, Pleural effusion, Cardiomegaly ํ™•์ธ

(8) ์„ ํ–‰ ์š”์ธ ๊ฐ๋ณ„ ์œ„ํ•œ ์ถ”๊ฐ€ ํ˜ˆ์•ก ๊ฒ€์‚ฌ ์‹œํ–‰

F. Treatment of symptomatic hypothyroidism

โ€ข
์ฆ์ƒ ์žˆ๋Š” ํ™˜์ž์—์„œ ํ™•์ง„์ด ๋˜๋ฉด ED์—์„œ oral levothyroxine ์‹œ์ž‘.
โ€ข
Levothyroxine (1.6 mcg/kg, ํ‰๊ท  ์‹œ์ž‘์€ 50 mcg/d) : 50์„ธ ์ด์ƒ์ด๊ฑฐ๋‚˜ cardiac disease ์žˆ๋Š” ๊ฒฝ์šฐ half dose๋กœ (12.5~25 mcg/d)

G. Treatment of myxedema crisis

โ€ข
Myxedema coma ์˜์‹ฌ ์‹œ laboratory confirmation์„ ๊ธฐ๋‹ค๋ฆฌ์ง€ ๋ง๊ณ  ๋ฐ”๋กœ ์น˜๋ฃŒ ์‹œ์ž‘!
โ€ข
Supportive care + Thyroid hormone replacement + Precipitating factor ํ™•์ธ & ์น˜๋ฃŒ

G1. Supportive care

(1) ์˜์‹๋ณ€ํ™” ๋ฐ ํ˜ธํก๋ถ€์ „ โ†’ Intubation์ด ํ•„์š”ํ•œ ๊ฒฝ์šฐ๊ฐ€ ๋งŽ๋‹ค.
(2) T3 ํˆฌ์—ฌ ํ›„ ๋ถ€์ •๋งฅ ๋ฐœ์ƒ ๊ฐ€๋Šฅ โ†’ Cardiac monitoring ํ•„์š”ํ•จ.
(3) ์ €์ฒด์˜จ ์น˜๋ฃŒ : Passive rewarming (blanket ์‚ฌ์šฉ)
(4) Hypoglycemia โ†’ Dextrose containing IV fluid๋กœ ๊ต์ •
(5) Hyponatremia ๊ต์ •
(6) IV hydrocortisones (ํŠนํžˆ, ์ €ํ˜ˆ์••์ด ์žˆ์„ ๋•Œ)
โ€ข
100mg IV every 8hrs for first 24hrs โ†’ Thyroid hormone replacement ์ „์— ์ฒซ dose๋ฅผ ๋จผ์ € ํˆฌ์—ฌํ•œ๋‹ค.
(7) ๊ฒฝํ—˜์  ํ•ญ์ƒ์ œ ํˆฌ์—ฌ : Infection์ด ํ”ํ•œ precipitating cause์ด๋ฏ€๋กœ.
(8) TSH, T4, T3, cortisol baseline level โ†’ ์น˜๋ฃŒ ๊ฐœ์‹œ ์ „์— ์ฑ„ํ˜ˆํ•˜๋„๋ก ํ•จ.

G2. Thyroid replacement

(1) ์‹œ์ž‘์€ ๋ฐ˜๋“œ์‹œ IV route

โ€ข
์žฅ์šด๋™๊ณผ GI ํก์ˆ˜๊ฐ€ ๊ฐ์†Œ๋˜์–ด ์žˆ์–ด์„œโ†’ ํ™˜์ž ์ƒํƒœ ํ˜ธ์ „(ambulation ๊ฐ€๋Šฅ) ํ›„ PO๋กœ ๋ณ€๊ฒฝ

(2) T4 alone, T4 & T3 combination, T3 alone ??

โ†’ ๋ฌด์—‡์ด ์ข‹์€์ง€๋Š” ์•„์ง ์ž˜ ๋ชจ๋ฅธ๋‹ค.

(3) Severe myxedema coma ํ™˜์ž์—์„œ๋Š” T3 ํˆฌ์—ฌ๋ฅผ ๊ณ ๋ ค

โ€ข
์ด๋Ÿฐ ํ™˜์ž๋“ค์—์„œ๋Š” T4์—์„œ T3(active hormone)๋กœ conversion ์‹œํ‚ค๋Š” ๋Šฅ๋ ฅ์ด ๋–จ์–ด์ ธ ์žˆ๊ธฐ ๋•Œ๋ฌธ
โ€ข
ํ•˜์ง€๋งŒ T3๋Š” ๋ถ€์ •๋งฅ ์œ ๋ฐœ์ด T4๋ณด๋‹ค ํ”ํ•˜๋ฏ€๋กœ compromised myocardial function ์žˆ๋Š” ํ™˜์ž์—์„œ ์‚ฌ์šฉ ์‹œ ์ฃผ์˜๊ฐ€ ํ•„์š”ํ•จ.
โ€ข
๋น ๋ฅธ onset of action, but highly fluctuating serum levels

(4) T4 : Smooth, slow, steady onset of action

โ€ข
Large therapeutic dose์—์„œ ๋ถ€์ •๋งฅ ๋ฐ MI ์œ ๋ฐœ ์ธก๋ฉด์—์„œ T3 ๋ณด๋‹ค ์•ˆ์ „ํ•จ.

G3. Identify and Tx. precipitating and cormorbid factors

H. Dispostion and follow-up

1.
Myxedema coma : High mortality(30~60%) โ†’ ICU admission
2.
Poor prognostic factors : Advanced age, bradycardia, persistent hypotension

I. Special populations

I1. Pregnant women

(1) Metabolism์˜ ์ฆ๊ฐ€๋กœ thyroid hormone ์š”๊ตฌ๋Ÿ‰์ด ์ฆ๊ฐ€๋จ. (๋Œ€๋žต 30% ์ฆ๊ฐ€)
(2) ์‚ฐ๋ชจ์—์„œ TFT๊ฐ€ normal์ด์–ด๋„ hypothyroidism์˜ ์ฆ์ƒ์ด ์žˆ๋Š” ๊ฒฝ์šฐ ์‹ค์ œ euthyroid๊ฐ€ ์•„๋‹ ์ˆ˜ ์žˆ๋‹ค.
(3) ์‚ฐ๋ชจ์˜ subclinical hypthyroidism์€ ์น˜๋ฃŒ ๋Œ€์ƒ์ž„.
(4) Myxedema crisis์˜ ๊ฒฝ์šฐ IV levothyroxine์ด ์•ˆ์ „ํ•˜๊ฒŒ ์‚ฌ์šฉ ๊ฐ€๋Šฅ.

I2. Elderly / Cardiac patietns

(1) Myxedema crisis ์‹œ ์˜ˆํ›„๊ฐ€ ๋ถˆ๋Ÿ‰. ์น˜๋ฃŒ ํ•„์š” ์‹œ ๋ณดํ†ต ์น˜๋ฃŒ ์šฉ๋Ÿ‰์˜ ์ตœ๊ณ  ๋ฐ˜์œผ๋กœ ์‹œ์ž‘.

I3. Thyroxine hormone overdose

(1) 24์‹œ๊ฐ„ ์ „์—๋Š” ๋Œ€๋ถ€๋ถ„ ์ฆ์ƒ ๋ฐœํ˜„ํ•˜์ง€ ์•Š์Œ (T4 โ†’ T3 ์ „ํ™˜ ํ•„์š”)
(2) ์ ๋ฆฝ๋œ ์น˜๋ฃŒ๋ฒ•์€ ์—†์Œ. ํ™œ์„ฑํƒ„ ํˆฌ์—ฌ ๊ฐ€๋Šฅ.
(3) Cholestyramine์œผ๋กœ fecal elimination ์ฆ๊ฐ€. Propranolol๋กœ ๋นˆ๋งฅ ๋ฐ ๋ถˆ์•ˆ ์กฐ์ ˆ